Q-omics provides the consensus-scored ALK profile across patient tissues and cancer cell-line models. ALK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ALK is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ALK RNA expression shows 15,992 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where ALK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALK survival associations across molecular data types. ALK RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALK RNA expression–survival associations across cancer types. High ALK expression shows unfavorable associations in UCEC, STAD, BLCA, ACC and UVM, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ALK RNA expression.
This table summarizes ALK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ALK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALK shows lower tumor expression in COAD and BRCA and higher tumor expression in THCA, HNSC, KIRC and KIRP. The THCA box plot shows higher ALK RNA expression in tumor versus normal tissue (log2 FC = +1.470, t-test p < 0.001).
This table shows molecular features associated with ALK in patient tissues and cancer cell lines. In patient samples, ALK shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ALK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
